Anzeige
Erschienen in:
07.07.2022
Low-energy (360 J) radiofrequency catheter ablation using moderate power − short duration: proof of concept based on in silico modeling
Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 5/2023
Einloggen, um Zugang zu erhaltenAbstract
Background
Pilot clinical studies suggest that very high power–very short duration (vHPvSD, 90 W/4 s, 360 J energy) is a feasible and safe technique for ablation of atrial fibrillation (AF), compared with standard applications using moderate power–moderate duration (30 W/30 s, 900 J energy). However, it is unclear whether alternate power and duration settings for the delivery of the same total energy would result in similar lesion formation. This study compares temperature dynamics and lesion size at different power-duration settings for the delivery of equivalent total energy (360 J).
Methods
An in silico model of radiofrequency (RF) ablation was created using the Arrhenius function to estimate lesion size under different power-duration settings with energy balanced at 360 J: 30 W/12 s (MPSD), 50 W/7.2 s (HPSD), and 90 W/4 s (vHPvSD). Three catheter orientations were considered: parallel, 45°, and perpendicular.
Results
In homogenous tissue, vHPvSD and HPSD produced similar size lesions independent of catheter orientation, both of which were slightly larger than MPSD (lesion size 0.1 mm deeper, ~ 0.7 mm wider, and ~ 25 mm3 larger volume). When considering heterogeneous tissue, these differences were smaller. Tissue reached higher absolute temperature with vHPvSD and HPSD (5–8 °C higher), which might increase risk of collateral tissue injury or steam pops.
Conclusion
Ablation for AF using MPSD or HPSD may be a feasible alternative to vHPvSD ablation given similar size lesions with similar total energy delivery (360 J). Lower absolute tissue temperature and slower heating may reduce risk of collateral tissue injury and steam pops associated with vHPvSD and longer applications using moderate power.